- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Rapid Micro Biosystems - Articles and news items
The rapid microbiological methods revolution.
Controlling contamination in the pharmaceutical industry.
Rapid Micro Methods Roundtable.
Rapid Micro Biosystems announced that it has raised $32.6 million in series B financing…
Rapid Method Development and Quality Regulatory Submissions – Combining UPLC, Quality-by-Design (QbD) and Software-Guided Validation
During this webinar learn from industry experts some practices to help better manage the investigation process and how to design processes to minimize unnecessary excursions…
This pharma webinar demonstrates best practices to help better manage the investigation process and how to design processes to minimize unnecessary excursions.
Experts in this pharma webinar demonstrate how rapid technologies, like the Growth Direct™ System can have an impact on microbial quality control and ultimately manufacturing.
New applications improve the efficiency of microbial quality control processes…
Issue 4 2011 / 31 August 2011 / Steve Delity, CEO, Rapid Micro Biosystems
Rapid Micro Biosystems is a privately owned, venture backed company with headquarters in Bedford, Massachusetts. Since launching its GrowthDirect™ System in 2008, the company has now moved into Europe with the opening of its new demo centre in Darmstadt, Germany in June 2011. So, how does CEO Steve Delity view the current situation in the pharmaceutical industry? “The power of pharmaceutical research and development is so massive that there will always be blockbusters, but will we see the prevalence, the frequency, the number of blockbusters we’ve had in the past? It’s a more efficient deployment of resources to take known drugs and look at whether it’s possible to increase their efficacy or decrease the side effects. The hunt for the next big blockbuster will always be there, but you can spend a lot of money and come up with nothing in the end, which is a huge risk.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics